Css LLC Il Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Css LLC Il decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,751 shares of the biopharmaceutical company’s stock after selling 500 shares during the quarter. Css LLC Il’s holdings in Gilead Sciences were worth $1,732,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Redwood Financial Network Corp grew its stake in Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares in the last quarter. Nicolet Advisory Services LLC lifted its position in shares of Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 100 shares during the last quarter. Southland Equity Partners LLC grew its position in shares of Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 110 shares during the last quarter. Berkshire Bank lifted its holdings in Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 111 shares during the last quarter. Finally, CFO4Life Group LLC boosted its stake in Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 112 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the sale, the chief financial officer now owns 168,174 shares in the company, valued at approximately $17,893,713.60. This represents a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 22,929 shares of company stock valued at $2,634,220. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 25th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Stock Up 2.8%

Shares of Gilead Sciences stock opened at $109.11 on Wednesday. The company has a market cap of $135.73 billion, a P/E ratio of 294.89, a P/E/G ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a 50-day moving average price of $105.51 and a 200 day moving average price of $100.02.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the firm earned ($1.32) EPS. The company’s revenue was down .3% compared to the same quarter last year. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.90%. Gilead Sciences’s dividend payout ratio is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.